Reclipsen Related Published Studies
Well-designed clinical trials related to Reclipsen (Desogestrel / Estradiol)
Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. [2007.12]
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. [2006.04]
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. [2005.06]
Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene. [2004.06]
A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. [2004.04]
Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. [2003.08]
A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. [2003.06]
Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. [2002.12]
Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. [2002.12]
Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. [2002.01]
Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. [2001.09]
Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. [2001.07]
Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. [2001.03]
Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/150 microg desogestrel. [2000.09]
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. [2000.07]
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. [2000.07]
Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. [2000.07]
Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. [2000.05]
Single monthly administration of the anti-progestagen Org 31710 in users of the 75 microg desogestrel progestagen-only pill: effects on pituitary-ovarian activity. [2000.03]
A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. [2000.02.15]
A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system. [2000.02]
A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. [1999.11]
Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta. [1999.10]
A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. [1999.09]
Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. [1999.05]
A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. [1999.04]
Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene. [1999]
A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. [1998.12]
Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. [1998.09]
Well-designed clinical trials possibly related to Reclipsen (Desogestrel / Estradiol)
Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. [2008.08]
Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. [2008.02]
Use of the NuvaRing(R) hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus. [2008.02]
The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. [2008.02]
Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use. [2007.11]
7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. [2007.09]
Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. [2007.02]
Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. [2007.01]
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. [2006.12]
Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. [2006.09]
Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. [2006.09]
Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. [2006.05.20]
Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. [2006.04]
Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. [2006.03.20]
Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. [2006.01]
A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. [2006.01]
A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. [2006.01]
Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. [2005.11]
Extended regimens of the contraceptive vaginal ring: a randomized trial. [2005.09]
Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. [2005.05]
20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. [2005.04.18]
Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. [2005.04]
A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. [2005.02]
Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. [2005]
Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]
Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]
Effects of hormonal contraception on bone mineral density after 24 months of use. [2004.05]
Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. [2004.04]
The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. [2004.03]
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. [2004.02.01]
Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. [2004.02]
The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]
Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. [2003.12]
Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. [2003.10]
A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. [2003.05]
Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. [2003.05]
The combined contraceptive ring NuvaRing and spermicide co-medication. [2003.04]
The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. [2003.03]
Complete and robust ovulation inhibition with NuvaRing. [2002.12]
Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. [2002.08]
Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction. [2002.08]
Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. [2002.07]
[Ultrasonographic and lipid changes in polycystic ovary syndrome according to the type of treatment ] [2002.06]
Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. [2002.05]
Serum concentrations of markers of type I collagen metabolism in women taking monophasic oral contraceptives. [2002.02]
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. [2002.02]
Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. [2002.01]
Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. [2001.11]
Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. [2001.10]
The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. [2001.10]
Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women. [2001.09.28]
A scheme of combined oral contraceptives for women more than 40 years old. [2001.07]
Ovarian function during and after treatment with the new progestagen Org 30659. [2001.07]
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. [2001.05]
Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. [2000.09]
The effect of hormone replacement therapy on arterial distensibility and compliance in perimenopausal women: a 2-year randomised trial. [2000.09]
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. [2000.07]
Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. [2000.06]
Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. [2000.04]
Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. [2000.03]
A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. [2000.01]
Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. [2000]
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. [1999.12.11]
Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. [1999.12]
Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. [1999.11]
Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. [1999.08.16]
Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. [1999.04]
Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. [1999]
Other possibly related research studies
Trends in prescribing patterns of hormonal contraceptives for adolescents. [2008.04]
Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. [2008.04]
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. [2008.02]
Cerebral venous thrombosis as a complication of oral contraceptive use in a 15-year-old patient: a case report. [2007.07]
|
